AbSci
  • About Us
  • Careers
  • News
  • Contact
  • Facebook
  • Twitter
  • Linkedin
Select Page
AbSci Announces Completion of $125 Million Crossover Financing  to Advance AI-Powered Synthetic Biology Drug Creation Platform

AbSci Announces Completion of $125 Million Crossover Financing to Advance AI-Powered Synthetic Biology Drug Creation Platform

Mar 23, 2021 | News, Press, Uncategorized

Round was co-led by Casdin Capital and Redmile Group Fidelity Management & Research Company LLC, D1 Capital Partners, and Perceptive Advisors are among the new investors VANCOUVER, Wash., March 23, 2021 /PRNewswire/ — AbSci, a pioneering synthetic biology company...

AbSci Announces Strategic Investment by Merck Global Health Innovation Fund

Feb 22, 2021 | Uncategorized

VANCOUVER, Wash., – February 22, 2021 – AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, today announced a strategic equity investment by Merck Global Health Innovation Fund (Merck GHI) and potential...

AbSci Enters Biologics Development Collaboration with Xyphos Biosciences, an Astellas Company

Feb 3, 2021 | Uncategorized

-Second molecule addressed under the collaboration agreement, first to exploit AbSci discovery technologies-  VANCOUVER, Wash., February 3, 2021 /PRNewswire/ — AbSci, a pioneering synthetic biology company enabling drug discovery and biomanufacturing of...
AbSci Announces Acquisition of Deep Learning Company Denovium

AbSci Announces Acquisition of Deep Learning Company Denovium

Jan 12, 2021 | Uncategorized

Integration of Denovium Engine™ with AbSci’s Protein Printing™ Platform to enable creation of novel biotherapeutics and manufacturing cell lines with the click of a button  Vancouver, Wash., January 12, 2021 – AbSci, a leading synthetic biology company enabling drug...
AbSci to Present at the 39th Annual J.P. Morgan Healthcare Conference

AbSci to Present at the 39th Annual J.P. Morgan Healthcare Conference

Jan 7, 2021 | Uncategorized

VANCOUVER, Wash., Jan. 7, 2021 /PRNewswire/ — AbSci, a leading synthetic biology company enabling drug discovery and biomanufacturing of next generation biotherapeutics, today announced that Sean McClain, Founder and CEO, will present virtually at the 39th...
« Older Entries

Recent Posts

  • AbSci Announces Completion of $125 Million Crossover Financing to Advance AI-Powered Synthetic Biology Drug Creation Platform
  • AbSci Announces Strategic Investment by Merck Global Health Innovation Fund
  • AbSci Enters Biologics Development Collaboration with Xyphos Biosciences, an Astellas Company
  • AbSci Announces Acquisition of Deep Learning Company Denovium
  • AbSci to Present at the 39th Annual J.P. Morgan Healthcare Conference

Archives

  • March 2021
  • February 2021
  • January 2021
  • November 2020
  • October 2020
  • September 2020
  • January 2020
  • July 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • July 2018
  • May 2018
  • February 2018
  • January 2018
  • December 2017
  • October 2017
  • August 2017
  • April 2017
  • January 2017
  • October 2016
  • August 2016
  • May 2016
  • April 2016
  • October 2015
SEE ARCHIVE

Categories

  • Announcement
  • Article
  • Award
  • Fundraising
  • News
  • Press
  • Uncategorized

Designed by Elegant Themes | Powered by WordPress